UNH Stock Rally Loses Momentum After Failed Break Above $400, Back to $300?

Quick overview

UnitedHealth Group’s rebound lost momentum after the stock briefly climbed above the key $400 level, as lingering healthcare cost concerns and regulatory risks continued to weigh on investor confidence.

UnitedHealth Recovery Struggles to Hold Momentum

UnitedHealth Group shares extended their recovery rally in recent sessions as improving cost trends across the health insurance industry boosted sentiment toward the sector. The stock briefly moved above the important $400 resistance level for the first time since the sharp collapse in May 2025, signaling growing optimism that the company may be stabilizing after a difficult period.

However, the rally quickly lost strength. Buyers failed to maintain momentum above the breakout level, and the stock reversed lower, highlighting continued uncertainty surrounding the company’s longer-term outlook.

Berkshire Hathaway Dumps UNH Shares

Investor sentiment had previously been damaged after Berkshire Hathaway fully exited its 3.3 million-share position in UnitedHealth during the first quarter, a move that intensified concerns about the company’s near-term prospects.

The broader rebound in healthcare insurers was partly fueled by stronger-than-expected earnings from Centene Corporation, which improved confidence that medical cost pressures may finally be easing across the industry. UnitedHealth also benefited from the improving sector sentiment after months of weakness tied to rising healthcare expenses, regulatory uncertainty, and concerns over profitability.

Financial Results Support Stabilization Narrative

UnitedHealth’s recent quarterly results helped reinforce the view that operational conditions are improving. First-quarter revenue reached $111.7 billion, representing a 2% increase from the previous year, while adjusted earnings per share came in at $7.23, exceeding analyst expectations.

The company also showed meaningful improvement in profitability metrics. Operating margins at UnitedHealthcare expanded from 6.2% to 6.6%, while the Medical Care Ratio declined significantly to 83.9% from 88.9% in the prior quarter, suggesting that healthcare cost pressures may be moderating.

UnitedHealth additionally reduced its Medicare Advantage membership by roughly 1.3 million members during 2026 as part of a broader effort to improve efficiency and protect margins.

Stock Rebounds on Earnings and Momentum

UnitedHealth Group shares have surged higher in the last two months, climbing back above the $400 level after beating Q1 earnings expectations and the Cantene news but failed to hold gains above that level. The move builds on an earlier rebound in April, when the stock gained momentum following favorable policy developments.

UNH Chart Weekly – Breaking Above the 100 SMA

After a difficult period in early 2025, the recent price action has been bullish, sending UNH stock price above the 50 weekly SMA (yellow) which acted as resistance in 2025. The rally revived hopes of a broader recovery, especially after pushing above 400, but the 100 SMA (green) stopped the climb and UNH pulled back below that level. A sustained move above $400 would signal a more definitive return to an uptrend toward $500, otherwise if buyers can’t hold above $400 then the price will likely reverse back down.

UnitedHealth Group Q1 Earnings

Financial Performance:

• UnitedHealth Group reported Q1 2026 adjusted earnings per share of $7.23, significantly higher than expectations.
• Total Q1 revenues were $111.7 billion, demonstrating a 2% growth year-over-year, significantly influenced by disciplined pricing actions and member mix adjustments.
• The medical care ratio improved, reporting at 83.9% compared to 84.8% in Q1 2025, reflecting strong medical cost management and favorable reserve developments.
• The operating cost ratio stood at 13.8% for the quarter.

Business Progress:

• Optum Health showed positive results with adjusted earnings of $1.3 billion, benefits arising from prior period restatements and improved core performance.
• Reported strong membership dynamics and engagement in AI-enabled healthcare technologies, like the deployment of Avery, a generative AI chatbot.
• Optum RX and Optum Insight businesses are capitalizing on new client onboarding and AI-first products, contributing to substantial operational improvements.

Financial Guidance:

• Expect continued revenue growth with strategic investments in AI and technology expected to primarily benefit the second half of the fiscal year.
• Membership in government programs expected to show moderate attrition with marginal improvement in margins beginning in 2027.
• Anticipate deploying at least $2 billion in share repurchases by the end of Q2, with projections of continued investment in strategic acquisitions.

Opportunities:

• AI investments across the business units are poised to improve operational efficiencies, customer engagement, and healthcare outcomes, with substantial financial returns projected.
• Growth in Optum RX and Optum Insight is driven by increasing client base and implementing innovative AI-driven solutions.

Risks:

• Persistent elevated medical trends particularly in Medicare Advantage, alongside insufficient state funding for Medicaid impacting margins.
• Regulatory adjustments and compliance with new health policies remain areas of concern, requiring vigilant management and strategic adjustments.

Medicare Policy Update Provides Relief

Additional support came after the Centers for Medicare & Medicaid Services approved a 2.48% increase in Medicare Advantage payment rates for 2027. Because UnitedHealth maintains major exposure to the Medicare Advantage market, the policy change improved visibility around future revenue growth and profitability.

Still, risks remain elevated. Regulatory scrutiny across the healthcare industry continues to intensify, and investors remain cautious that medical cost inflation could reaccelerate if utilization trends worsen again.

Although UnitedHealth’s strong balance sheet, diversified business structure, and consistent cash flow generation continue to support the recovery narrative, the failed move above $400 showed that market confidence remains fragile and vulnerable to renewed pressure.

ABOUT THE AUTHOR See More

Skerdian Meta

Lead Analyst

Skerdian Meta Lead Analyst. Skerdian is a professional Forex trader and a market analyst. He has been actively engaged in market analysis for the past 11 years. Before becoming our head analyst, Skerdian served as a trader and market analyst in Saxo Bank's local branch, Aksioner. Skerdian specialized in experimenting with developing models and hands-on trading. Skerdian has a masters degree in finance and investment.

UNH Stock Finally Breaches $400 as Medicare Outlook and Margins Improve

2 weeks ago

Save

UNH Stock Reclaims $350 after Beating Q1, Raising FY26 Guidance, But $380 Is Key Level

1 month ago

Save

UnitedHealth From Collapse to Comeback and Down Again—Where Will the UNH Stock Head in 2026?

4 months ago

Save